Levetiracetam (Keppra) IV to Oral Conversion
When transitioning from intravenous to oral levetiracetam, use the same dose and frequency—the formulations are bioequivalent with 100% oral bioavailability, allowing for a 1:1 conversion without dose adjustment. 1
Dosing Equivalence
The FDA-approved labeling for Keppra confirms that oral tablets and solution have 100% bioavailability, making them directly interchangeable with IV formulations 1. This is supported by bioequivalence studies demonstrating that:
- AUC (area under curve): IV/oral ratio of 92.2% (90% CI: 89.0-95.6%)
- Cmax: IV/oral ratio of 103.7% (90% CI: 91.6-117.4%)
These values fall within the standard bioequivalence range, confirming therapeutic equivalence 2.
Practical Conversion Guidelines
Standard Maintenance Dosing
- If receiving 500 mg IV every 12 hours → Switch to 500 mg PO every 12 hours
- If receiving 1000 mg IV every 12 hours → Switch to 1000 mg PO every 12 hours
- If receiving 1500 mg IV every 12 hours → Switch to 1500 mg PO every 12 hours
The conversion is straightforward: match the IV dose exactly with the oral dose at the same frequency 1.
Timing Considerations
Food delays absorption by 1.5 hours and reduces Cmax by 20%, but does not affect total drug exposure 1. Therefore:
- Levetiracetam can be given with or without food
- No dose adjustment needed based on meal timing
- The clinical impact of delayed Cmax is minimal for maintenance therapy
Special Populations
Renal Impairment
If the patient has renal dysfunction, maintain the same dose adjustment strategy used for IV therapy when converting to oral 1:
- CrCl 50-80 mL/min: 500-1000 mg every 12 hours
- CrCl 30-50 mL/min: 250-750 mg every 12 hours
- CrCl <30 mL/min: 250-500 mg every 12 hours
- ESRD on dialysis: 500-1000 mg every 24 hours (with 250-500 mg supplemental dose post-dialysis)
Pediatric Patients
For children, the weight-based dosing remains identical when switching routes 1:
- Maintain the same mg/kg/dose and frequency
- Use oral solution for patients ≤20 kg
- Tablets or solution acceptable for patients >20 kg
Clinical Pearls
Steady-state achievement: Both IV and oral formulations reach steady state within 48 hours of twice-daily dosing 1, 2. This means the conversion can occur at any point without concern for subtherapeutic levels.
No loading dose needed: When converting from IV to oral at steady state, no additional loading is required—simply continue the same maintenance regimen 3.
Absorption characteristics: Peak plasma concentrations occur approximately 1 hour after oral administration in fasted subjects 1. The rapid absorption profile supports reliable seizure control when transitioning from IV therapy.
Common Pitfalls to Avoid
- Do not reduce the oral dose assuming lower bioavailability—this is unnecessary and risks breakthrough seizures
- Do not extend dosing intervals when switching to oral—maintain the every 12-hour schedule
- Do not delay conversion in stable patients who can take oral medications—the oral formulation is equally effective 3
The evidence consistently demonstrates that levetiracetam IV and oral formulations are therapeutically equivalent, allowing for seamless transitions in clinical practice without dose modification 2, 4.